Brief: Caliway Biopharmaceuticals Expects IND Approvals For Cbl-514
23/10/2024 17:02
Oct 23 (Reuters) - Caliway Biopharmaceuticals Co Ltd
6919.TW :
* CALIWAY BIOPHARMACEUTICALS-EXPECTS IND APPROVALS FOR
CBL-514
FROM U.S. FDA,HEALTH CANADA BY 2025, SUBJECT RECRUITMENT
EXPECTED TO INITIATE IN H2 2025
Source text for Eikon: ID:nPn588R4ha
Further company coverage: 6919.TW
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CALIWAY BIOPHARMACEUTICALS
See all newsBrief: Caliway: New Drug CBL-514 Phase II Clinical Results' Demonstrated Efficacy
Brief: Caliway Says A Phase 2B Study For Reducing Abdominal Subcutaneous Fat Met All Main Goals
Brief: Caliway Announced EMA Orphan Drug Designation Granted To CBL-514 For Dercum's Disease Treatment
Brief: Caliway Biopharmaceuticals Expects IND Approvals For Cbl-514